In addition to aberrations in 520 targeted genes, we also characterized detection of clinically relevant NSCLC drivers, including those in EGFR, KRAS, ALK, ROS1, BRAF, MET, RET, and NTRK1/2/3. Here, BRAF is linked to non-small cell lung carcinoma.